iVS-1® lactose intolerance clinical study completed

Synbiotic Health is pleased to announce that a randomized, double-blinded, clinical trial to assess the ability of its flagship probiotic strain (B. adolescentis iVS-1®) to reduce symptoms associated with lactose intolerance was recently completed by researchers at Purdue University.

This pilot study, soon to be submitted for publication, showed that participants who consumed iVS-1® had improved symptom scores compared to the placebo group. The genome of iVS-1® was previously found to feature genes involved in lactose metabolism, and this trial provides important real-world evidence for its potential application for improving symptoms of lactose intolerance in humans.